Hims & Hers Health, Inc. Class A Common Stock (HIMS)
25.54
-0.90 (-3.40%)
NYSE · Last Trade: Feb 3rd, 5:05 PM EST
Detailed Quote
Previous Close
26.44
Open
26.56
Bid
25.43
Ask
25.49
Day's Range
24.64 - 26.82
52 Week Range
23.97 - 72.98
Volume
21,259,803
Market Cap
4.90B
PE Ratio (TTM)
48.19
EPS (TTM)
0.5
Dividend & Yield
N/A (N/A)
1 Month Average Volume
16,996,020
Chart
About Hims & Hers Health, Inc. Class A Common Stock (HIMS)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care. The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery. Read More
Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2025 financial results after the market closes on Monday, February 23, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day.
Shareholders of Hims & Hers Health would probably like to forget the past six months even happened. The stock dropped 57.1% and now trades at $27.15. This may have investors wondering how to approach the situation.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately
as healthcare stocks have returned 17.4% over the past six months, topping the S&P 500 by 7.8 percentage points.
Netflix may be forced to offer all cash for WBD if the cable assets being spun off don't have the value Netflix thought they did. But is that something Netflix will do, and what are the risks?
Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, announced that it’s heading back to the Big Game this year. On February 8th, Hims & Hers will follow up its hit “Sick of the System” ad, debuting a new national spot “Rich People Live Longer” with a simple message: the era of health as a luxury good is over, and proactive, life-changing care belongs to everyone.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 2.2% in the morning session after Morgan Stanley reiterated its Equalweight rating but voiced concerns about the company's slowing growth and increasing competition.
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution.
While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.
As the calendar turns to 2026, the landscape for weight-loss and diabetes medication has been fundamentally transformed. What began two years ago as a "wild west" of $1,000-a-month list prices and chronic shortages has evolved into a highly competitive, government-influenced market where affordability and accessibility have finally taken center
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on.
However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.
As the final trading days of 2025 approach, the Nasdaq has reached a staggering milestone that has both bulls and bears on edge. According to the latest settlement data released on December 15, 2025, total short interest across the Nasdaq exchange has surged to a record 18.38 billion shares.
Hims & Hers has drawn scrutiny for selling compounded GLP-1 treatments – lower-cost, unapproved alternatives to blockbuster weight-loss drugs made by Eli Lilly and Novo Nordisk.
Profitability is a key measure of business strength.
Companies with high margins have proven they can generate consistent earnings while maintaining financial discipline.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks.
But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.
Hims & Hers is deepening its commitment to the UK by bringing access to its comprehensive Weight Loss Programme to customers. This expansion includes the official introduction of the Hers platform, helping eligible women across the UK receive access to this holistic weight management care.
